The treatment discussion as a whole has been impacted by the launch of new classes of treatment and new products over the past year. One third (10/30) of newly approved molecules in the European Union in 2016 were drugs for…
As we convened with our global oncology colleagues and look toward the future of cancer research at ASCO 2017, Verilogue analysts have taken a last look at 2016 to see how two basic conversation “vital signs” have evolved in the…